Dae Ho Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dae Ho Lee has a total of 527 co-authors. Here are the top co-authors by number of shared publications:
- Tae Min Kim
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
23 shared publications - Ignacio Melero
Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, 31008 Pamplona, Spain
18 shared publications - Victor Moreno
START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
18 shared publications - Byoung Chul Cho
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
17 shared publications - Fiona Thistlethwaite
Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, UK
17 shared publications - Kristoffer Staal Rohrberg
Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
17 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Table S8. Response assessment per RECIST version 1.1.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Table S8. Response assessment per RECIST version 1.1.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Supplementary Figure S1 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Supplementary Figure S1 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Table S5. snRNA-Seq sample overview.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Table S5. snRNA-Seq sample overview.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
S6. Overview of adverse events.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
S6. Overview of adverse events.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Table S4 Immune Gene Signatures.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Table S4 Immune Gene Signatures.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Supplementary Fig. 5. Single-nuclei RNA sequencing analyses depicting gene-signature pharmacodynamic effects in NK cells from selected patients. The heatmap colors and significance annotations follow the same scheme as in Fig. 4d. Adj, adjusted; C, cycle; D, day.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Supplementary Fig. 5. Single-nuclei RNA sequencing analyses depicting gene-signature pharmacodynamic effects in NK cells from selected patients. The heatmap colors and significance annotations follow the same scheme as in Fig. 4d. Adj, adjusted; C, cycle; D, day.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Table S3 Antibodies used for flow cytometry.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Table S3 Antibodies used for flow cytometry.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Table S7. Treatment-related grade 3 to 5 and serious adverse events.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Table S7. Treatment-related grade 3 to 5 and serious adverse events.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Table S2 Immunohistochemistry and immunofluorescent assay details.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Table S2 Immunohistochemistry and immunofluorescent assay details.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Table S1 Representativeness of Study Participants.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1–LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma
Table S1 Representativeness of Study Participants.